Helping patients with unmet medical needs in the field of immune reconstitution.

Thymofox is developing targeted, orally available medicines for thymus regeneration – unlocking the power of the adaptive immune system in patients.

our science

Unlocking the power of the adaptive immune system

Thymus regeneration

Our adaptive immune system depends on a healthy thymus. Susceptibility to disease dramatically increases with thymus degeneration.

Thymus function degenerates with normal aging. Thymus degeneration also happens in response to sickness and stress, and as a side effect of some modern medical interventions.

Targeted medicines

Our sophisticated tools, engineered in human thymus cells, have generated a pipeline of compounds with diverse pharmacology targeting thymus regeneration.

We use sophisticated fingerprinting techniques to determine how our drug candidates modulate regenerative pathways. Fingerprinting allows us to better understand the targeted mechanism of action and select biomarkers to identify the most responsive patients.

Oral bioavailability

Immune reconstitution by thymus regeneration is an unmet need at the level of population health. Current solutions to restore immune function, such as processed thymus tissue from tissue donors, cannot meet the scale needed.

Small molecule drugs that can be taken by mouth will have the greatest impact on patients across multiple therapeutic indications.

Thymofox pledges to partner with patients as we work to discover and develop new, effective therapies for immune reconstitution by thymus regeneration including treatments in oncology, vaccines, and age-related decline in immune function

The News

Thymofox Signals Continued Growth and Expansion with New Executive and Science Team Hires

12.12.2023
press release

Thymofox Signals Continued Growth and Expansion with New Executive and Science Team Hires

12.12.2022
press release

Thymofox Signals Continued Growth and Expansion with New Executive and Science Team Hires

11.12.2023
media

Thymofox Signals Continued Growth and Expansion with New Executive and Science Team Hires

4.16.2023

Thymofox Signals Continued Growth and Expansion with New Executive and Science Team Hires

The Team

Investors & Partners

Memorial Sloan Kettering Cancer Center LogoApollo Health Ventures Logo

Team

Christopher R.  Shepard,

Christopher R. Shepard,

PhD, MBA

Co-Founder & CEO
John  Proudfoot,

John Proudfoot,

PhD

Head of Medicinal Chemistry
Jarrod Dudakov,

Jarrod Dudakov,

PhD

Scientific Co-Founder
Marcel R.M.  van den Brink,

Marcel R.M. van den Brink,

MD, PhD

Scientific Co-Founder
Jens Eckstein,

Jens Eckstein,

PhD

Board Director
Dr. Ole Mensching

Dr. Ole Mensching

Board Director

About

ThymoFox Inc.
Corporate Office
1 Broadway
Cambridge, MA 02142
USA

Thymofox has laboratory operations in the US and the EU.

Get in touch with us

Your message
*required
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.